



Clinical trial results:

Phase III, Multinational, Multicenter, Investigator-Masked, Randomised, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocular Hypertension over a 3-Month period, followed by a 12-Month Follow-Up with Open-Label DE-130A Treatment

Summary

EudraCT number	2017-004262-95
Trial protocol	FI GB DE EE PL ES BE AT LV IT
Global end of trial date	26 October 2022

Results information

Result version number	v1 (current)
This version publication date	12 November 2023
First version publication date	12 November 2023

Trial information

Trial identification

Sponsor protocol code	0130A01SA
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04133311
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Santen S.A.S.
Sponsor organisation address	1 Rue Pierre Fontaine, Genavenir IV, Evry cedex, France, F-91058
Public contact	Regulatory Affairs EMEA, Santen S.A.S., regulatoryaffairs@santen.com
Scientific contact	Regulatory Affairs EMEA, Santen S.A.S., regulatoryaffairs@santen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 November 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	03 February 2022
Global end of trial reached?	Yes
Global end of trial date	26 October 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate that the intraocular pressure (IOP) reducing effect of DE-130A (latanoprost 50 µg/ml preservative-free eye drops emulsion) is non-inferior to that of Xalatan® [latanoprost 50 µg/ml Benzalkonium Chloride (BAK)-preserved eye drops solution] in patients with Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) at Week 12 without using any rescue medication(s).

Protection of trial subjects:

This study was conducted in accordance with International Council for Harmonisation (ICH) of Good Clinical Practice (GCP), ethical principles that have their origin in the Declaration of Helsinki as well as other applicable ethical and regulatory requirements.

The final protocol, its amendments, and Informed Consent Form (ICF), relevant supporting information, and patient recruitment information were submitted by the Investigator to an Independent Ethics Committee (IEC) and/or Institutional Review Board (IRB) and approved by the IEC/IRB prior to study initiation.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 April 2019
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	12 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 9
Country: Number of subjects enrolled	Spain: 43
Country: Number of subjects enrolled	United Kingdom: 13
Country: Number of subjects enrolled	Austria: 7
Country: Number of subjects enrolled	Belgium: 11
Country: Number of subjects enrolled	Estonia: 29
Country: Number of subjects enrolled	Finland: 5
Country: Number of subjects enrolled	France: 4
Country: Number of subjects enrolled	Germany: 15
Country: Number of subjects enrolled	Italy: 37
Country: Number of subjects enrolled	Latvia: 26
Country: Number of subjects enrolled	Russian Federation: 181
Country: Number of subjects enrolled	Korea, Republic of: 6

Worldwide total number of subjects	386
EEA total number of subjects	186

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	198
From 65 to 84 years	186
85 years and over	2

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Out of 488 patients screened, 386 were randomised at Visit 1, n=193 to the DE-130A group and n=193 to the control (Xalatan®) group.

Out of 137 patients who participated in Period 2, 71 had previously been treated with DE-130A and 66 with Xalatan® during Period 1. All 137 subjects were administered at least one dose of DE-130A.

Period 1

Period 1 title	Double Masked Treatment Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind ^[1]
Roles blinded	Investigator, Monitor, Data analyst

Blinding implementation details:

Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT.

DE-130A: Latanoprost 50 microg/ml eye drops emulsion, eye drops emulsion in single-dose containers

Arms

Are arms mutually exclusive?	Yes
Arm title	Period 1: DE-130A

Arm description:

DE-130A: Latanoprost 50 microg/ml preservative-free eye drops emulsion, eye drops emulsion in single-dose containers.

Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT.

Arm type	Experimental
Investigational medicinal product name	DE-130A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Eye drops, emulsion
Routes of administration	Ophthalmic use

Dosage and administration details:

Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s).

Arm title	Period 1: Xalatan
------------------	-------------------

Arm description:

Xalatan: Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.

Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OH.

Arm type	Active comparator
Investigational medicinal product name	Xalatan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Eye drops, solution
Routes of administration	Ophthalmic use

Dosage and administration details:

Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s).

Notes:

[1] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: The patients did not be explicitly told about the name of the study drug by the drug dispensing staff.

Number of subjects in period 1	Period 1: DE-130A	Period 1: Xalatan
Started	193	193
Completed	190	190
Not completed	3	3
Adverse event, serious fatal	1	-
Consent withdrawn by subject	1	1
Adverse event, non-fatal	1	1
Sponsor Temporarily Discontinued Study	-	1

Period 2

Period 2 title	Open Label Treatment Period
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Period 2: DE-130A/DE-130A

Arm description:

DE-130A: Latanoprost 50 microg/ml preservative-free eye drops emulsion, eye drops emulsion in single-dose containers.

After 12 weeks, participants continued to use DE-130A for additional 12 months. Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT.

Arm type	Open-label
Investigational medicinal product name	DE-130A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Eye drops, emulsion
Routes of administration	Ophthalmic use

Dosage and administration details:

Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s).

Arm title	Period 2: Xalatan/DE-130A
------------------	---------------------------

Arm description:

DE-130A: Latanoprost 50 microg/ml preservative-free eye drops emulsion, eye drops emulsion in single-dose containers.

After 12 weeks, participants were converted to use DE-130A instead of Xalatan®. Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT.

Arm type	Open-label
----------	------------

Investigational medicinal product name	DE-130A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Eye drops, emulsion
Routes of administration	Ophthalmic use

Dosage and administration details:

Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s).

Number of subjects in period 2 ^[2]	Period 2: DE-130A/DE-130A	Period 2: Xalatan/DE-130A
Started	71	66
Completed	67	62
Not completed	4	4
Consent withdrawn by subject	2	2
Early Terminated	1	-
Adverse event, non-fatal	-	2
Pregnancy	1	-

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: It was defined in protocol as follows, and the number of subjects is as planned. The first 130 patients who completed the week 12 visit and agreed to participate in the open-label period of the study were followed for 12 months from week 12 and received open-label DE-130A treatment.

Baseline characteristics

Reporting groups

Reporting group title	Period 1: DE-130A
-----------------------	-------------------

Reporting group description:

DE-130A: Latanoprost 50 microg/ml preservative-free eye drops emulsion, eye drops emulsion in single-dose containers.

Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT.

Reporting group title	Period 1: Xalatan
-----------------------	-------------------

Reporting group description:

Xalatan: Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.

Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT.

Reporting group values	Period 1: DE-130A	Period 1: Xalatan	Total
Number of subjects	193	193	386
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	103	95	198
From 65-84 years	88	98	186
85 years and over	2	0	2
Age continuous			
Units: years			
arithmetic mean	62.3	63.9	
standard deviation	\pm 12.04	\pm 10.13	-
Gender categorical			
Units: Subjects			
Female	121	117	238
Male	72	76	148

End points

End points reporting groups

Reporting group title	Period 1: DE-130A
Reporting group description: DE-130A: Latanoprost 50 microg/ml preservative-free eye drops emulsion, eye drops emulsion in single-dose containers. Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT.	
Reporting group title	Period 1: Xalatan
Reporting group description: Xalatan: Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers. Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OH.	
Reporting group title	Period 2: DE-130A/DE-130A
Reporting group description: DE-130A: Latanoprost 50 microg/ml preservative-free eye drops emulsion, eye drops emulsion in single-dose containers. After 12 weeks, participants continued to use DE-130A for additional 12 months. Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT.	
Reporting group title	Period 2: Xalatan/DE-130A
Reporting group description: DE-130A: Latanoprost 50 microg/ml preservative-free eye drops emulsion, eye drops emulsion in single-dose containers. After 12 weeks, participants were converted to use DE-130A instead of Xalatan®. Instillation of one drop, once daily in the evening (9 pm \pm 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT.	

Primary: Intraocular Pressure (IOP) Reduction (mmHg) at Week 12

End point title	Intraocular Pressure (IOP) Reduction (mmHg) at Week 12
End point description: The primary efficacy endpoint was the change from baseline in peak (9:00 am \pm 1 hour) and trough (4:00 pm \pm 1 hour) IOPs, respectively, at Week 12 between the two treatment groups in the study eye.	
End point type	Primary
End point timeframe: Week 12: Peak (9:00 am \pm 1 hour) and trough (4:00 pm \pm 1 hour)	

End point values	Period 1: DE-130A	Period 1: Xalatan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	189		
Units: mmHg				
least squares mean (standard error)				
peak (9:00 am \pm 1 hour)	-8.8 (\pm 0.25)	-8.2 (\pm 0.26)		

Statistical analyses

Statistical analysis title	PRIMARY EFFICACY ENDPOINT
Statistical analysis description:	
The primary efficacy endpoint was change from baseline in peak and trough IOP at Week 12 in the study eye. Non-inferiority was established if the upper limit of the one-sided 97.5% CI is ≤ 1.5 mmHg at both the peak and trough timepoints.	
Comparison groups	Period 1: DE-130A v Period 1: Xalatan
Number of subjects included in analysis	377
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Mean difference (final values)
Point estimate	0
Confidence interval	
level	Other: 97.5 %
sides	1-sided
upper limit	1.5
Variability estimate	Standard deviation
Dispersion value	4.26

Primary: Intraocular Pressure (IOP) Reduction (mmHg) at Week 12

End point title	Intraocular Pressure (IOP) Reduction (mmHg) at Week 12
End point description:	
The primary efficacy endpoint was the change from baseline in peak (9:00 am \pm 1 hour) and trough (4:00 pm \pm 1 hour) IOPs, respectively, at Week 12 between the two treatment groups in the study eye.	
End point type	Primary
End point timeframe:	
Week 12 (16:00) trough timepoint	

End point values	Period 1: DE-130A	Period 1: Xalatan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	186	188		
Units: mmHg				
least squares mean (standard error)				
(16:00) trough timepoint	-8.6 (\pm 0.24)	-8.1 (\pm 0.25)		

Statistical analyses

Statistical analysis title	PRIMARY EFFICACY ENDPOINT
Statistical analysis description:	
The primary efficacy endpoint was change from baseline in peak and trough IOP at Week 12 in the study eye. Non-inferiority was established if the upper limit of the one-sided 97.5% CI is ≤ 1.5 mmHg at both the peak and trough timepoints.	
Comparison groups	Period 1: DE-130A v Period 1: Xalatan
Number of subjects included in analysis	374
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Mean difference (final values)
Point estimate	0
Confidence interval	
level	Other: 97.5 %
sides	1-sided
upper limit	1.5
Variability estimate	Standard deviation
Dispersion value	4.26

Secondary: Corneal Fluorescein Staining (CFS) Change From Baseline (First Key Secondary Endpoint)

End point title	Corneal Fluorescein Staining (CFS) Change From Baseline (First Key Secondary Endpoint)
End point description:	
CSF Change from baseline in participants with baseline CSF score ≥ 1 at Week 12.	
End point type	Secondary
End point timeframe:	
At Week 12	

End point values	Period 1: DE-130A	Period 1: Xalatan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	80	86		
Units: Score				
least squares mean (standard error)	-0.71 (\pm 0.069)	-0.41 (\pm 0.077)		

Statistical analyses

No statistical analyses for this end point

Secondary: Ocular Surface Disease (OSD) Symptoms (Average of 3 Symptoms); Second Key Secondary Endpoint

End point title	Ocular Surface Disease (OSD) Symptoms (Average of 3 Symptoms); Second Key Secondary Endpoint
End point description:	
Change from baseline in OSD symptom score (average of 3 symptoms: dry eye sensation, blurred/poor	

vision and burning/stinging/itching) in the study eye at Week 12 in patients with baseline symptom average score>0.

End point type	Secondary
----------------	-----------

End point timeframe:

at Week 12

End point values	Period 1: DE-130A	Period 1: Xalatan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99	104		
Units: Score				
least squares mean (standard error)	-0.26 (± 0.058)	-0.17 (± 0.060)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Information about AEs were collected from the signing of consent form until the end of the study.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

Reporting groups

Reporting group title	DE-130A
-----------------------	---------

Reporting group description: -

Reporting group title	Xalatan
-----------------------	---------

Reporting group description: -

Reporting group title	DE-130A/DE-130A
-----------------------	-----------------

Reporting group description: -

Reporting group title	Xalatan/DE-130A
-----------------------	-----------------

Reporting group description: -

Serious adverse events	DE-130A	Xalatan	DE-130A/DE-130A
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 193 (0.52%)	2 / 193 (1.04%)	0 / 71 (0.00%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	1	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bladder cancer			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure acute			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary thrombosis			

subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Xalatan/DE-130A		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 66 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bladder cancer			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardiac failure acute			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pulmonary thrombosis			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	DE-130A	Xalatan	DE-130A/DE-130A
Total subjects affected by non-serious adverse events			
subjects affected / exposed	35 / 193 (18.13%)	42 / 193 (21.76%)	21 / 71 (29.58%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Blepharal papilloma			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 71 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			

Hypertension subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Surgical and medical procedures Knee arthroplasty subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	1 / 193 (0.52%) 1	0 / 71 (0.00%) 0
Dental implantation subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Chest pain subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	1 / 193 (0.52%) 1	0 / 71 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	1 / 193 (0.52%) 1	0 / 71 (0.00%) 0
Instillation site pain subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	3 / 193 (1.55%) 3	0 / 71 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	2 / 193 (1.04%) 2	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Rhinorrhoea			

subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	1 / 193 (0.52%) 1	0 / 71 (0.00%) 0
Investigations			
Blood cholesterol increased subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	2 / 193 (1.04%) 2	0 / 71 (0.00%) 0
Injury, poisoning and procedural complications			
Tooth fracture subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	1 / 193 (0.52%) 1	0 / 71 (0.00%) 0
Skin laceration subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Cardiac disorders			
Angina pectoris subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Palpitations subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	2 / 193 (1.04%) 2	1 / 193 (0.52%) 1	0 / 71 (0.00%) 0
Dysgeusia subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0

Eye disorders			
Ocular hyperaemia			
subjects affected / exposed	3 / 193 (1.55%)	5 / 193 (2.59%)	2 / 71 (2.82%)
occurrences (all)	3	5	2
Conjunctival hyperaemia			
subjects affected / exposed	2 / 193 (1.04%)	3 / 193 (1.55%)	1 / 71 (1.41%)
occurrences (all)	2	3	1
Dry eye			
subjects affected / exposed	2 / 193 (1.04%)	1 / 193 (0.52%)	1 / 71 (1.41%)
occurrences (all)	2	1	1
Erythema of eyelid			
subjects affected / exposed	2 / 193 (1.04%)	2 / 193 (1.04%)	0 / 71 (0.00%)
occurrences (all)	2	2	0
Keratitis			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 71 (0.00%)
occurrences (all)	2	0	0
Vision blurred			
subjects affected / exposed	2 / 193 (1.04%)	0 / 193 (0.00%)	0 / 71 (0.00%)
occurrences (all)	2	0	0
Blepharitis			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	2 / 71 (2.82%)
occurrences (all)	1	0	2
Chalazion			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	1 / 71 (1.41%)
occurrences (all)	1	0	1
Conjunctival haemorrhage			
subjects affected / exposed	1 / 193 (0.52%)	1 / 193 (0.52%)	0 / 71 (0.00%)
occurrences (all)	1	1	0
Conjunctival oedema			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 71 (0.00%)
occurrences (all)	1	0	0
Eye pain			
subjects affected / exposed	1 / 193 (0.52%)	1 / 193 (0.52%)	1 / 71 (1.41%)
occurrences (all)	1	1	1
Eye pruritus			

subjects affected / exposed	1 / 193 (0.52%)	3 / 193 (1.55%)	0 / 71 (0.00%)
occurrences (all)	1	3	0
Eyelid oedema			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 71 (0.00%)
occurrences (all)	1	0	0
Growth of eyelashes			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	2 / 71 (2.82%)
occurrences (all)	1	0	2
Ocular discomfort			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 71 (0.00%)
occurrences (all)	1	0	0
Swelling of eyelid			
subjects affected / exposed	1 / 193 (0.52%)	2 / 193 (1.04%)	1 / 71 (1.41%)
occurrences (all)	1	3	1
Abnormal sensation in eye			
subjects affected / exposed	0 / 193 (0.00%)	4 / 193 (2.07%)	1 / 71 (1.41%)
occurrences (all)	0	4	2
Eye irritation			
subjects affected / exposed	0 / 193 (0.00%)	2 / 193 (1.04%)	0 / 71 (0.00%)
occurrences (all)	0	2	0
Foreign body sensation in eyes			
subjects affected / exposed	0 / 193 (0.00%)	3 / 193 (1.55%)	0 / 71 (0.00%)
occurrences (all)	0	3	0
Lacrimal disorder			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 71 (0.00%)
occurrences (all)	0	1	0
Vitreous detachment			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	1 / 71 (1.41%)
occurrences (all)	0	1	1
Cataract			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 71 (1.41%)
occurrences (all)	0	0	2
Eye paraesthesia			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 71 (1.41%)
occurrences (all)	0	0	1
Retinal haemorrhage			

subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Visual impairment subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Vitreous floaters subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Macular fibrosis subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Photopsia subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Gastrointestinal disorders Burning mouth syndrome subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	1 / 193 (0.52%) 1	0 / 71 (0.00%) 0
Skin and subcutaneous tissue disorders Hyperkeratosis subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	3 / 193 (1.55%) 3	1 / 193 (0.52%) 1	0 / 71 (0.00%) 0
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1

Pain in extremity subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	3 / 193 (1.55%) 3	0 / 71 (0.00%) 0
Mobility decreased subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	1 / 193 (0.52%) 1	0 / 71 (0.00%) 0
Osteoarthritis subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	1 / 193 (0.52%) 1	1 / 71 (1.41%) 1
Plantar fasciitis subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Tendon disorder subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Spinal pain subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Infections and infestations			
Bronchitis subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	2 / 193 (1.04%) 2	0 / 71 (0.00%) 0
Influenza subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 193 (0.52%) 1	2 / 193 (1.04%) 2	0 / 71 (0.00%) 0
Subcutaneous abscess			

subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 71 (0.00%)
occurrences (all)	1	0	0
Tooth infection			
subjects affected / exposed	1 / 193 (0.52%)	0 / 193 (0.00%)	0 / 71 (0.00%)
occurrences (all)	1	0	0
Cystitis			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 71 (0.00%)
occurrences (all)	0	1	0
Genital infection			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 71 (0.00%)
occurrences (all)	0	1	0
Labyrinthitis			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 71 (0.00%)
occurrences (all)	0	1	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 71 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 193 (0.00%)	1 / 193 (0.52%)	0 / 71 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 71 (1.41%)
occurrences (all)	0	0	1
Conjunctivitis viral			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 71 (1.41%)
occurrences (all)	0	0	1
Ear infection			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 71 (1.41%)
occurrences (all)	0	0	1
Herpes simplex			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 71 (1.41%)
occurrences (all)	0	0	1
Hordeolum			
subjects affected / exposed	0 / 193 (0.00%)	0 / 193 (0.00%)	1 / 71 (1.41%)
occurrences (all)	0	0	1
Rhinitis			

subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1
Coronavirus infection subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	0 / 71 (0.00%) 0
Metabolism and nutrition disorders Gout subjects affected / exposed occurrences (all)	0 / 193 (0.00%) 0	0 / 193 (0.00%) 0	1 / 71 (1.41%) 1

Non-serious adverse events	Xalatan/DE-130A		
Total subjects affected by non-serious adverse events subjects affected / exposed	21 / 66 (31.82%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Blepharal papilloma subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Surgical and medical procedures Knee arthroplasty subjects affected / exposed occurrences (all) Dental implantation subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0 1 / 66 (1.52%) 1		
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all) Chest pain	0 / 66 (0.00%) 0		

<p>subjects affected / exposed</p> <p>0 / 66 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Fatigue</p> <p>subjects affected / exposed</p> <p>0 / 66 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Instillation site pain</p> <p>subjects affected / exposed</p> <p>1 / 66 (1.52%)</p> <p>occurrences (all)</p> <p>1</p>			
<p>Pain</p> <p>subjects affected / exposed</p> <p>1 / 66 (1.52%)</p> <p>occurrences (all)</p> <p>1</p>			
<p>Immune system disorders</p> <p>Seasonal allergy</p> <p>subjects affected / exposed</p> <p>0 / 66 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Oropharyngeal pain</p> <p>subjects affected / exposed</p> <p>0 / 66 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Rhinorrhoea</p> <p>subjects affected / exposed</p> <p>0 / 66 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Investigations</p> <p>Blood cholesterol increased</p> <p>subjects affected / exposed</p> <p>0 / 66 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Body temperature increased</p> <p>subjects affected / exposed</p> <p>0 / 66 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Injury, poisoning and procedural complications</p> <p>Tooth fracture</p> <p>subjects affected / exposed</p> <p>0 / 66 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Contusion</p> <p>subjects affected / exposed</p> <p>0 / 66 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			

Skin laceration subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Cardiac disorders Angina pectoris subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Palpitations subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Dysgeusia subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Eye disorders Ocular hyperaemia subjects affected / exposed occurrences (all)	2 / 66 (3.03%) 2		
Conjunctival hyperaemia subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1		
Dry eye subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Erythema of eyelid subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1		
Keratitis subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Vision blurred			

subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Blepharitis			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	1		
Chalazion			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Conjunctival haemorrhage			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Conjunctival oedema			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Eye pain			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	2		
Eye pruritus			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	1		
Eyelid oedema			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Growth of eyelashes			
subjects affected / exposed	2 / 66 (3.03%)		
occurrences (all)	2		
Ocular discomfort			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Swelling of eyelid			
subjects affected / exposed	2 / 66 (3.03%)		
occurrences (all)	3		
Abnormal sensation in eye			
subjects affected / exposed	4 / 66 (6.06%)		
occurrences (all)	4		
Eye irritation			

subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Foreign body sensation in eyes			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	1		
Lacrimonal disorder			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Vitreous detachment			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Cataract			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Eye paraesthesia			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Retinal haemorrhage			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Visual impairment			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Vitreous floaters			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Macular fibrosis			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	1		
Photopsia			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	1		
Gastrointestinal disorders			
Burning mouth syndrome			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		

Diarrhoea subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Skin and subcutaneous tissue disorders Hyperkeratosis subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1		
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Pain in extremity subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Back pain subjects affected / exposed occurrences (all)	2 / 66 (3.03%) 2		
Mobility decreased subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1		
Osteoarthritis subjects affected / exposed occurrences (all)	1 / 66 (1.52%) 1		
Plantar fasciitis subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		
Tendon disorder subjects affected / exposed occurrences (all)	0 / 66 (0.00%) 0		

Spinal pain			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	1		
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
COVID-19			
subjects affected / exposed	4 / 66 (6.06%)		
occurrences (all)	4		
Influenza			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Subcutaneous abscess			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Tooth infection			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Cystitis			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Genital infection			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Labyrinthitis			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Lower respiratory tract infection			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Respiratory tract infection viral			

subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Conjunctivitis viral			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Ear infection			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Herpes simplex			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Hordeolum			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Rhinitis			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Coronavirus infection			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Gout			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported